$532.94▴ 2.62%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
85th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
+6.2%year over year
Healthy
Revenue is growing at a steady pace.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 22% below our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
United Therapeutics Corporation's earnings-quality signal is not available yet. Revenue is growing at a steady pace. Its valuation sits in the richer end of its own recent range.
Key numbers
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.